Neurology

publication venue for

Association of Self-Reported Sleep Characteristics With Neuroimaging Markers of Brain Aging Years Later in Middle-Aged Adults.. 103:-. 2024
Life's Essential 8 and Poor Brain Health Outcomes in Middle-Aged Adults.. 103:-. 2024
Association of Seizure Control With Cognition in People With Normal Cognition and Mild Cognitive Impairment.. 103:-. 2024
Association of Changes in C-Reactive Protein Level Trajectories Through Early Adulthood With Cognitive Function at Midlife: The CARDIA Study.. 103:-. 2024
The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.. 103:-. 2024
Long-Term Depressive Symptom Trajectories and Midlife Cognition: The CARDIA Study.. 103:-. 2024
Associations Between Self and Study Partner Report of Cognitive Decline With Regional Tau in a Multicohort Study.. 102:-. 2024
Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments.. 102:-. 2024
Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging.. 102:-. 2024
Associations of Polycystic Ovary Syndrome With Indicators of Brain Health at Midlife in the CARDIA Cohort.. 102:-. 2024
Screening for Cognitive Decline in Isolated/Idiopathic REM Sleep Behavior Disorder: Which Test Is Best?. 102:-. 2024
Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy Consortium.. 102:-. 2024
Association Between Sleep Quantity and Quality in Early Adulthood With Cognitive Function in Midlife.. 102:-. 2024
Association of Poor Oral Health With Neuroimaging Markers of White Matter Injury in Middle-Aged Participants in the UK Biobank.. 102:-. 2023
Emerging Subspecialties in Neurology: Women's Neurology.. 102:-. 2023
Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study.. 101:e2288-e2299. 2023
Clinical Reasoning: A 22-Year-Old Man With Multifocal Brain and Osseous Lesions.. 101:1025-1031. 2023
Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults.. 101:e2533-e2544. 2023
Frequency of Orthostatic Hypotension in Isolated REM Sleep Behavior Disorder.. 101:e2545-e2559. 2023
Associations Between Traumatic Brain Injury and Cognitive Decline Among Older Male Veterans: A Twin Study.. 101:e1761-e1770. 2023
Clinical Reasoning: A 48-Year-Old Man With Spasticity and Progressive Ataxia.. 101:e1747-e1752. 2023
Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.. 101:e1402-e1411. 2023
Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared With Corticolimbic Alzheimer Disease Subtypes.. 101:e1412-e1423. 2023
Polygenic Susceptibility to Hypertension and Cognitive Performance in Middle-aged Persons Without Stroke or Dementia.. 101:e512-e521. 2023
Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome.. 101:e289-e299. 2023
Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life Span.. 101:e164-e177. 2023
Associations of Enlarged Perivascular Spaces With Brain Lesions, Brain Age, and Clinical Outcomes in Chronic Traumatic Brain Injury.. 101:e63-e73. 2023
Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease.. 101:e20-e29. 2023
Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts.. 100:e1930-e1943. 2023
Evaluating the Association Between Genetically Proxied Neurodevelopmental Language Phenotypes and the Risk of Primary Progressive Aphasia.. 100:e1922-e1929. 2023
Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.. 101:172-180. 2023
Premature Cardiovascular Disease and Brain Health in Midlife: The CARDIA Study.. 100:e1454-e1463. 2023
Polygenic Susceptibility to Hypertension and Blood Pressure Control in Stroke Survivors.. 100:e1587-e1597. 2023
Interim Safety Profile From the Feasibility Study of the BrainGate Neural Interface System.. 100:e1177-e1192. 2023
Cognitive and Functional Trajectories in Older Adults With Prediagnostic Parkinson Disease.. 100:e1386-e1394. 2022
Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis.. 100:e911-e920. 2022
Combined Effects of Synaptic and Axonal Integrity on Longitudinal Gray Matter Atrophy in Cognitively Unimpaired Adults.. 99:e2285-93. 2022
Association of Obesity With Cognitive Decline in Black and White Americans.. 100:e220-e231. 2022
Estimating Bidirectional Transitions and Identifying Predictors of Mild Cognitive Impairment.. 100:e297-e307. 2022
Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.. 100:e275-e285. 2022
Migraine, Migraine Disability, Trauma, and Discrimination in Sexual and Gender Minority Individuals.. 99:e1549-e1559. 2022
Opinion and Special Article: The Need for Specialized Training in Women's Neurology.. 100:38-42. 2022
Socioeconomic Status, Biological Aging, and Memory in a Diverse National Sample of Older US Men and Women.. 99:e2114-e2124. 2022
The Case for Light Physical Activity and Brain Health: Every Move Counts.. 99:455-456. 2022
Association of β-Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy.. 99:e270-80. 2022
Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease.. 98:e2436-45. 2022
Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.. 99:e594-e604. 2022
Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults: A Machine Learning Approach Using A4 Data.. 98:e2425-e2435. 2022
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.. 99:e245-e257. 2022
Prediction of Naming Outcome With FMRI Language Lateralization in Left Temporal Epilepsy Surgery.. 98:e2337-e2346. 2022
Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies.. 98:e2140-e2149. 2022
Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms.. 98:e2132-e2139. 2022
Association of Emerging β-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.. 98:e1512-e1524. 2022
Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment.. 98:e2036-e2045. 2022
Associations of Lower Extremity Peripheral Nerve Impairment and Risk of Dementia in Black and White Older Adults.. 98:e1837-e1845. 2022
Cerebral Microbleeds, Cerebral Amyloid Angiopathy, and Their Relationships to Quantitative Markers of Neurodegeneration.. 98:e1605-e1616. 2022
Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI: The A4 Study.. 98:e1327-e1336. 2022
Cognitive Outcome 1 Year After Mild Traumatic Brain Injury: Results From the TRACK-TBI Study.. 98:e1248-e1261. 2022
Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline.. 98:e1337-e1348. 2022
Twenty-Five-Year Change in Cardiac Structure and Function and Midlife Cognition: The CARDIA Study.. 98:e1040-e1049. 2022
Adherence to Antiseizure vs Other Medications Among US Medicare Beneficiaries With and Without Epilepsy.. 98:e427-36. 2022
Teaching NeuroImage: Neurovascular Consequences of Autonomic Dysreflexia.. 98:e441-e442. 2022
Association of Cognitive Impairment With Free Water in the Nucleus Basalis of Meynert and Locus Coeruleus to Transentorhinal Cortex Tract.. 98:e700-e710. 2021
Physiology and Clinical Relevance of Enlarged Perivascular Spaces in the Aging Brain.. 98:107-117. 2021
Simulation-Based Assessment of Graduate Neurology Trainees' Performance Managing Acute Ischemic Stroke.. 97:e2414-e2422. 2021
Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-β PET Signal.. 97:e1799-e1808. 2021
Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.. 97:e1823-e1834. 2021
Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.. 97:e1334-e1342. 2021
Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease.. 97:543-544. 2021
Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.. 96:e2933-43. 2021
Experience of Community Neurologists Providing Care for Patients With Neurodegenerative Illness During the COVID-19 Pandemic.. 97:e988-e995. 2021
Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia.. 97:e523-e534. 2021
Progressive Neurologic Symptoms in the Setting of HIV: A Rare Case of Neurosymptomatic CSF HIV Escape.. 97:389-390. 2021
Association of Aortic Stiffness With Biomarkers of Neuroinflammation, Synaptic Dysfunction, and Neurodegeneration.. 97:e329-e340. 2021
Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease.. 97:e76-e87. 2021
Visit-to-Visit Blood Pressure Variability, Neuropathology, and Cognitive Decline.. 96:e2812-e2823. 2021
Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis.. 96:e2546-e2557. 2021
APOE. 96:e2414-e2428. 2021
Association of Refractory Pain in the Acute Phase After Subarachnoid Hemorrhage With Continued Outpatient Opioid Use.. 96:e2355-e2362. 2021
Cardiovascular Risk Factors Across the Life Course and Cognitive Decline: A Pooled Cohort Study.. 96:e2212-e2219. 2021
APOE. 96:e2272-e2283. 2021
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome.. 96:848-863. 2021
Traumatic Brain Injury and Incidence Risk of Sleep Disorders in Nearly 200,000 US Veterans.. 96:e1792-e1799. 2021
Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults.. 96:e1844-e1854. 2021
Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.. 96:e1491-e1500. 2021
Child Neurology: Intractable Epilepsy and Transient Deficits in a Patient With a History of Herpes Simplex Virus Encephalitis.. 96:679-681. 2021
Memory Resilience in Alzheimer Disease With Primary Progressive Aphasia.. 96:e916-e925. 2021
Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease.. 96:e1470-e1481. 2021
Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort.. 96:e2500-e2512. 2021
APOE4. 96:e650-e661. 2020
Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation.. 96:e619-e631. 2020
Comparison of Clinical Outcomes 1 and 5 Years Post-Injury Following Combat Concussion.. 96:e387-e398. 2020
Association of Angiotensin II-Stimulating Antihypertensive Use and Dementia Risk: Post Hoc Analysis of the PreDIVA Trial.. 96:e67-e80. 2020
Apathy and risk of probable incident dementia among community-dwelling older adults.. 95:e3280-e3287. 2020
Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial.. 95:e2658-e2665. 2020
Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model.. 95:e2666-e2674. 2020
The impact of delirium on withdrawal of life-sustaining treatment after intracerebral hemorrhage.. 95:e2727-e2735. 2020
Sex, race, and risk of dementia diagnosis after traumatic brain injury among older veterans.. 95:e1768-e1775. 2020
Association of genetic risk for Alzheimer disease and hearing impairment.. 95:e2225-e2234. 2020
Decline in kidney function over the course of adulthood and cognitive function in midlife.. 95:e2389-e2397. 2020
Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study.. 95:e3104-e3116. 2020
Apolipoprotein E. 95:e2086-e2094. 2020
Clinician-judged hearing impairment and associations with neuropathologic burden.. 95:e1640-e1649. 2020
Familial language network vulnerability in primary progressive aphasia.. 95:e847-e855. 2020
Systolic blood pressure postural changes variability is associated with greater dementia risk.. 95:e1932-e1940. 2020
Cardiovascular risk factors and accelerated cognitive decline in midlife: The CARDIA Study.. 95:e839-e846. 2020
Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers.. 95:e1312-e1321. 2020
Blood biomarkers of traumatic brain injury and cognitive impairment in older veterans.. 95:e1126-e1133. 2020
The presubiculum links incipient amyloid and tau pathology to memory function in older persons.. 94:e1916-e1928. 2020
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.. 95:e320-e331. 2020
Anatomical evidence of an indirect pathway for word repetition.. 94:e594-e606. 2020
Differential neurocognitive network perturbation in amnestic and aphasic Alzheimer disease.. 94:e699-e704. 2020
Diet pattern and prodromal features of Parkinson disease.. 95:e2095-e2108. 2020
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. 94:481-494. 2020
GBA. 95:e685-e696. 2020
LRRK2. 95:e3428-e3437. 2020
Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology update.. 94:30-38. 2019
APOE. 94:e607-e612. 2019
Relation between 20-year income volatility and brain health in midlife: The CARDIA study.. 93:e1890-e1899. 2019
Navigating monoclonal antibody use in breastfeeding women: Do no harm or do little good?. 93:668-672. 2019
Clinical EEG slowing correlates with delirium severity and predicts poor clinical outcomes.. 93:e1260-e1271. 2019
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.. 93:e1647-e1659. 2019
Midlife adiposity predicts cognitive decline in the prospective Multicenter AIDS Cohort Study.. 93:e261-e271. 2019
Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults.. 93:e29-e39. 2019
Framing advance care planning in Parkinson disease: Patient and care partner perspectives.. 92:e2571-e2579. 2019
Dietary patterns during adulthood and cognitive performance in midlife: The CARDIA study.. 92:e1589-e1599. 2019
The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individuals.. 92:643-644. 2019
Perivascular spaces contribute to cognition beyond other small vessel disease markers.. 92:e1309-e1321. 2019
Vitamin D levels and risk of delirium: A mendelian randomization study in the UK Biobank.. 92:e1387-e1394. 2019
Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting.. 92:e486-503. 2019
Physical activity and prodromal features of Parkinson disease.. 93:e2157-e2169. 2019
Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis.. 92:e2089-e2100. 2019
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.. 92:329-337. 2019
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.. 93:e1328-e1338. 2019
Word comprehension in temporal cortex and Wernicke area: A PPA perspective.. 92:e224-e233. 2018
Military-related risk factors in female veterans and risk of dementia.. 92:e205-e211. 2018
CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury.. 91:702-709. 2018
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.. 91:e1295-e1306. 2018
APOE. 91:e1182-e1195. 2018
Utilizing semantic intrusions to identify amyloid positivity in mild cognitive impairment.. 91:e976-e984. 2018
Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease.. 91:e859-e866. 2018
Serum glutamine and hospital-acquired infections after aneurysmal subarachnoid hemorrhage.. 91:e421-e426. 2018
Baseline NAWM structural integrity and CBF predict periventricular WMH expansion over time.. 90:e2119-e2126. 2018
Mild TBI and risk of Parkinson disease: A Chronic Effects of Neurotrauma Consortium Study.. 90:e1771-e1779. 2018
APOE. 90:e1605-e1612. 2018
Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial.. 90:e1404-e1412. 2018
Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid.. 90:e1306-e1315. 2018
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.. 90:e877-e886. 2018
Neurogranin as a predictor of memory and executive function decline in MCI patients.. 90:e887-e895. 2018
Dementia and motor vehicle crash hospitalizations: Role of physician reporting laws.. 90:e808-e813. 2018
Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts.. 90:e1646-e1653. 2018
Neurology residency training in 2017: A survey of preparation, perspectives, and plans.. 92:76-83. 2018
Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis.. 92:e2081-e2088. 2018
Multiple pathways of reserve simultaneously present in cognitively normal older adults.. 90:e197-e205. 2017
Vascular and dopaminergic contributors to mild parkinsonian signs in older adults.. 90:e223-e229. 2017
Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.. 89:2381-2391. 2017
Lower cardiac index levels relate to lower cerebral blood flow in older adults.. 89:2327-2334. 2017
COL4A2. 89:1829-1839. 2017
Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.. 89:1877-1885. 2017
Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.. 89:1782-1788. 2017
Sex differences in the prevalence of genetic mutations in FTD and ALS: A meta-analysis.. 89:1633-1642. 2017
Subjective memory complaints in preclinical autosomal dominant Alzheimer disease.. 89:1464-1470. 2017
Longitudinal diffusion changes following postoperative delirium in older people without dementia.. 89:1020-1027. 2017
Developing an outline for teleneurology curriculum: AAN Telemedicine Work Group recommendations.. 89:951-959. 2017
Magnesium, hemostasis, and outcomes in patients with intracerebral hemorrhage.. 89:813-819. 2017
Slowing gait and risk for cognitive impairment: The hippocampus as a shared neural substrate.. 89:336-342. 2017
Functional network integrity presages cognitive decline in preclinical Alzheimer disease.. 89:29-37. 2017
BDNF. 88:2098-2106. 2017
Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment.. 88:2026-2035. 2017
A phase 3 trial of IV immunoglobulin for Alzheimer disease.. 88:1768-1775. 2017
Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden.. 88:1759-1767. 2017
Cued memory decline in biomarker-defined preclinical Alzheimer disease.. 88:1431-1438. 2017
Physical activity and hippocampal volume in middle-aged patients with type 1 diabetes.. 88:1564-1570. 2017
Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load.. 88:569-576. 2017
Intake of dairy foods and risk of Parkinson disease.. 89:46-52. 2017
Olfaction and risk of dementia in a biracial cohort of older adults.. 88:456-462. 2016
The link between sleep-disordered breathing and cognition in the elderly: New opportunities?. 88:424-425. 2016
Dementia risk in renal dysfunction: A systematic review and meta-analysis of prospective studies.. 88:198-208. 2016
Asymptomatic Alzheimer disease: Defining resilience.. 87:2443-2450. 2016
Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment.. 87:2317-2323. 2016
Slow gait, white matter characteristics, and prior 10-year interleukin-6 levels in older adults.. 87:1993-1999. 2016
Aphasic variant of Alzheimer disease: Clinical, anatomic, and genetic features.. 87:1337-43. 2016
Effects of hormone therapy on brain structure: A randomized controlled trial.. 87:887-96. 2016
Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly.. 87:920-6. 2016
Neuroimaging overuse is more common in Medicare compared with the VA.. 87:792-8. 2016
Polygenic risk of Alzheimer disease is associated with early- and late-life processes.. 87:481-8. 2016
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.. 87:539-47. 2016
Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.. 86:1887-96. 2016
Frontotemporal networks and behavioral symptoms in primary progressive aphasia.. 86:1393-1399. 2016
Hostile attitudes and effortful coping in young adulthood predict cognition 25 years later.. 86:1227-34. 2016
Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults.. 86:1208-16. 2016
Prospective study of plasma urate and risk of Parkinson disease in men and women.. 86:520-6. 2016
Memory complaints and risk of cognitive impairment after nearly 2 decades among older women.. 85:1852-8. 2015
Mediterranean diet and brain structure in a multiethnic elderly cohort.. 85:1744-51. 2015
Evaluation of outcome measures for neurogenic claudication: A patient-centered approach.. 85:1250-6. 2015
Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease.. 85:790-8. 2015
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.. 85:692-700. 2015
Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes.. 85:1131-8. 2015
Cognitive correlates of white matter lesion load and brain atrophy: the Northern Manhattan Study.. 85:441-9. 2015
Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers.. 85:48-55. 2015
Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly.. 85:56-62. 2015
Longitudinal patient-oriented outcomes in neuropathy: Importance of early detection and falls.. 85:71-9. 2015
Subclinical cerebrovascular disease inversely associates with learning ability: The NOMAS.. 84:2362-7. 2015
Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial.. 84:2338-46. 2015
Odor identification and Alzheimer disease biomarkers in clinically normal elderly.. 84:2153-60. 2015
Association of hospitalization with long-term cognitive and brain MRI changes in the ARIC cohort.. 84:1443-53. 2015
"Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis.. 84:617-22. 2015
PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease.. 84:972-80. 2015
Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures.. 84:729-37. 2015
Development and validation of risk index for cognitive decline using blood-derived markers.. 84:696-702. 2015
Inflammation, negative nitrogen balance, and outcome after aneurysmal subarachnoid hemorrhage.. 84:680-7. 2015
Nursing home and end-of-life care in Parkinson disease.. 85:413-9. 2015
Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community.. 84:182-9. 2014
Factors associated with cognitive evaluations in the United States.. 84:64-71. 2014
Physical activity attenuates age-related biomarker alterations in preclinical AD.. 83:1753-60. 2014
Cervical spine fracture associated with ankylosing spondylitis.. 83:-. 2014
Asymmetry of cortical decline in subtypes of primary progressive aphasia.. 83:1184-91. 2014
Vitamin D and the risk of dementia and Alzheimer disease.. 83:920-8. 2014
Traumatic brain injury and risk of dementia in older veterans.. 83:312-9. 2014
Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.. 83:253-60. 2014
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.. 82:1760-7. 2014
Cardiorespiratory fitness and cognitive function in middle age: the CARDIA study.. 82:1339-46. 2014
Contribution of Alzheimer disease to mortality in the United States.. 82:1045-50. 2014
Long-term survival after ischemic stroke in patients with atrial fibrillation.. 82:1033-7. 2014
Acute infection contributes to racial disparities in stroke mortality.. 82:914-21. 2014
Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study.. 82:435-42. 2014
Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration.. 82:1605-12. 2014
Supply and demand analysis of the current and future US neurology workforce.. 82:2254-5. 2014
Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men.. 81:2094-102. 2013
ω-3 fatty acids and domain-specific cognitive aging: secondary analyses of data from WHISCA.. 81:1484-91. 2013
The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study.. 81:1425-33. 2013
Naming vs knowing faces in primary progressive aphasia: a tale of 2 hemispheres.. 81:658-64. 2013
Neuropathologic basis of white matter hyperintensity accumulation with advanced age.. 81:977-83. 2013
Cocoa, neurovascular coupling, and neurodegeneration: the good, the bad, and the ugly.. 81:863-4. 2013
Imaging markers for Alzheimer disease: which vs how.. 81:487-500. 2013
Impaired default network functional connectivity in autosomal dominant Alzheimer disease.. 81:736-44. 2013
Clinical Reasoning: a 44-year-old woman with headache followed by sudden neurologic decline.. 80:e136-41. 2013
Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease.. 80:1194-201. 2013
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.. 80:1784-91. 2013
CSF biomarkers of Alzheimer disease: "noncognitive" outcomes.. 81:2028-31. 2013
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study.. 81:1531-7. 2013
Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI.. 81:534-40. 2013
Teaching Video NeuroImages: phenytoin-induced orofacial dyskinesias.. 79:-. 2012
Stroke symptoms signal worse outcomes in patients with end-stage renal disease.. 79:960-1. 2012
Trajectory of white matter hyperintensity burden preceding mild cognitive impairment.. 79:741-7. 2012
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.. 79:1636-44. 2012
Novel late-onset Alzheimer disease loci variants associate with brain gene expression.. 79:221-8. 2012
Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory.. 78:1464-71. 2012
Pearls & Oysters: the effects of renal replacement therapy on cerebral autoregulation.. 78:e36-8. 2012
Memory after silent stroke: hippocampus and infarcts both matter.. 78:38-46. 2012
CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.. 78:709-19. 2012
Caffeine in Parkinson disease: better for cruise control than snooze patrol?. 79:616-8. 2012
Habitual intake of dietary flavonoids and risk of Parkinson disease.. 78:1138-45. 2012
Indicators of amyloid burden in a population-based study of cognitively normal elderly.. 79:1570-7. 2012
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease.. 79:897-905. 2012
Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging.. 78:241-9. 2011
Effect of rebleeding on the course and incidence of vasospasm after subarachnoid hemorrhage.. 78:31-7. 2011
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.. 77:2034-42. 2011
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.. 77:1253-62. 2011
Advanced glycation end product level, diabetes, and accelerated cognitive aging.. 77:1351-6. 2011
Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment.. 77:125-31. 2011
Progression of language decline and cortical atrophy in subtypes of primary progressive aphasia.. 76:1804-10. 2011
Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution.. 76:1789-96. 2011
Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults.. 76:1395-402. 2011
Defaulting on the default network: increased risk for dementia.. 76:498-500. 2011
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease.. 76:501-10. 2011
Use of ibuprofen and risk of Parkinson disease.. 76:863-9. 2011
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.. 75:2087-96. 2010
Albuminuria and the risk of incident stroke and stroke types in older adults.. 75:1343-50. 2010
Use of anticholinergics and the risk of cognitive impairment in an African American population.. 75:152-9. 2010
Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline.. 74:1969-76. 2010
Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study.. 75:111-5. 2010
The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?. 75:1943-4; author reply 1944-5. 2010
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.. 73:2061-70. 2009
ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration.. 73:805-11. 2009
Conflict monitoring in early frontotemporal dementia.. 73:349-55. 2009
Cognitive impairment risk: white matter hyperintensity progression matters.. 73:120-5. 2009
Surrogate consent for dementia research: a national survey of older Americans.. 72:149-55. 2009
CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease.. 73:1982-7. 2009
Delirium accelerates cognitive decline in Alzheimer disease.. 72:1570-5. 2009
Family history of melanoma and Parkinson disease risk.. 73:1286-91. 2009
Obesity and restless legs syndrome in men and women.. 72:1255-61. 2009
Survival in Alzheimer disease: a multiethnic, population-based study of incident cases.. 71:1489-95. 2008
A novel PRNP-P105S mutation associated with atypical prion disease and a rare PrPSc conformation.. 71:1431-8. 2008
Fatigue in levodopa-naive subjects with Parkinson disease.. 71:481-5. 2008
Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.. 71:344-50. 2008
APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.. 70:1842-9. 2008
A longitudinal study of drivers with Alzheimer disease.. 70:1171-8. 2008
No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies.. 70:2291-8. 2008
Trajectories of brain loss in aging and the development of cognitive impairment.. 70:828-33. 2007
Vascular factors predict rate of progression in Alzheimer disease.. 69:1850-8. 2007
Relationship of fMRI activation to clinical trial memory measures in Alzheimer disease.. 69:1331-41. 2007
Mediterranean diet and Alzheimer disease mortality.. 69:1084-93. 2007
Does statin use decrease the amount of Alzheimer disease pathology in the brain?. 69:E8-11. 2007
Brain volumes in Guam dementia vs Parkinson dementia complex vs aging Chamorro adults.. 69:196-9. 2007
Impairment of nonverbal recognition in Alzheimer disease: a PET O-15 study.. 69:32-41. 2007
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study.. 68:1902-8. 2007
Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam.. 68:1764-71. 2007
Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE.. 68:1772-81. 2007
Predictors of diagnosis in Huntington disease.. 68:1710-7. 2007
AMPA potentiator treatment of cognitive deficits in Alzheimer disease.. 68:1008-12. 2007
Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.. 68:828-36. 2007
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.. 68:666-9. 2007
Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease.. 69:1688-95. 2007
Temporal relationship between cigarette smoking and risk of Parkinson disease.. 68:764-8. 2007
Multiple system atrophy presenting with language impairment.. 67:726-7. 2006
Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease.. 67:998-1005. 2006
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.. 67:1251-3. 2006
Projected costs of ischemic stroke in the United States.. 67:1390-5. 2006
Rapid infusion of cold saline (4 degrees C) as adjunctive treatment of fever in patients with brain injury.. 66:1739-41. 2006
Clinical features associated with costs in early AD: baseline data from the Predictors Study.. 66:1021-8. 2006
Brain volume loss in MCI predicts dementia.. 66:233-5. 2006
Inclusion-body myositis and Alzheimer disease: two sides of the same coin, or different currencies altogether?. 66:S65-8. 2006
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.. 66:602-4. 2006
fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease.. 65:1514-5; author reply 1514-5. 2005
Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD.. 65:404-11. 2005
Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease.. 65:159-62. 2005
Cognitive function predicts first-time stroke and heart disease.. 64:1750-5. 2005
Motor signs predict poor outcomes in Alzheimer disease.. 64:1696-703. 2005
Neuropsychological predictors of dependency in patients with Alzheimer disease.. 64:1027-31. 2005
Immunization therapy for Alzheimer disease?. 64:10-2. 2005
Physical activity and the risk of Parkinson disease.. 64:664-9. 2005
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.. 63:2084-90. 2004
Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial.. 63:1705-7. 2004
Motor signs during the course of Alzheimer disease.. 63:975-82. 2004
APOE-dependent PET patterns of brain activation in Alzheimer disease.. 63:913-5. 2004
Beta-synuclein gene alterations in dementia with Lewy bodies.. 63:805-11. 2004
Psychiatric comorbidities in patients with Parkinson disease and psychosis.. 63:293-300. 2004
Clinical profile and course of cognitively normal patients evaluated in memory disorders clinics.. 62:1639-42. 2004
Genetic influences on memory performance in familial Alzheimer disease.. 62:414-21. 2004
Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk.. 61:1185-90. 2003
Wrinkles and folds of the prion protein.. 61:1168-9. 2003
Changes in premorbid brain volume predict Alzheimer's disease pathology.. 61:487-92. 2003
Semantic memory deficit with a left thalamic infarct.. 61:252-4. 2003
Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study.. 60:1938-43. 2003
Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment.. 60:1467-73. 2003
Natural history of cognitive decline in the old old.. 60:1489-94. 2003
Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.. 60:1234-40. 2003
Predictors of nursing home placement in Huntington disease.. 60:998-1001. 2003
Spinal meningioma causing diffuse leptomeningeal enhancement.. 60:350-1. 2003
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.. 61:S74-81. 2003
Caffeine, postmenopausal estrogen, and risk of Parkinson's disease.. 60:790-5. 2003
Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.. 61:S62-8. 2003
Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.. 61:S55-61. 2003
Sleep regulation in adenosine A2A receptor-deficient mice.. 61:S94-6. 2003
The association of incident dementia with mortality in PD.. 59:1708-13. 2002
Premorbid weight, body mass, and varsity athletics in ALS.. 59:773-5. 2002
"Out, damned spot! out, I say!...": issues related to prion decontamination.. 59:488-9. 2002
Mortality in patients with dementia after ischemic stroke.. 59:537-43. 2002
Primary care expenditures before the onset of Alzheimer's disease.. 59:573-8. 2002
A national study of the quantity and cost of informal caregiving for the elderly with stroke.. 58:1754-9. 2002
Phases of A beta-deposition in the human brain and its relevance for the development of AD.. 58:1791-800. 2002
Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease.. 58:1182-8. 2002
The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function.. 58:1175-81. 2002
Functional deficits in patients with mild cognitive impairment: prediction of AD.. 58:758-64. 2002
Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy.. 58:115-9. 2002
Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.. 58:1154-60. 2002
Influence of leisure activity on the incidence of Alzheimer's disease.. 57:2236-42. 2001
Inherited prion disease caused by the V210I mutation: transmission to transgenic mice.. 57:2198-205. 2001
Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes.. 56:415-8. 2001
Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan.. 56:49-56. 2001
Presenilin-1-associated abnormalities in regional cerebral perfusion.. 56:1545-51. 2001
Different brain networks mediate task performance in normal aging and AD: defining compensation.. 55:1291-7. 2000
Late-onset SCA2: 33 CAG repeats are sufficient to cause disease.. 55:569-72. 2000
Motor impairment in PD: relationship to incident dementia and age.. 55:539-44. 2000
Poor verbal working memory across intellectual level in boys with Duchenne dystrophy.. 54:2127-32. 2000
Frequency and clinical determinants of dementia after ischemic stroke.. 54:1124-31. 2000
Rate of memory decline in AD is related to education and occupation: cognitive reserve?. 53:1942-7. 1999
Influence of APOE genotype on familial aggregation of AD in an urban population.. 53:789-94. 1999
Assessment of cognition in advanced AD: the test for severe impairment.. 52:1689-91. 1999
Selective decline in memory function among healthy elderly.. 52:1392-6. 1999
The influence of smoking on the risk of Alzheimer's disease.. 52:1408-12. 1999
Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia.. 52:719-24. 1999
Increased risk of mortality in AD patients with higher education?. 51:-. 1998
Creutzfeldt-Jakob disease (CJD) after blood product transfusion from a donor with CJD.. 50:1872-3. 1998
Cognitive test performance among nondemented elderly African Americans and whites.. 50:1238-45. 1998
Postmenopausal estrogen use and Parkinson's disease with and without dementia.. 50:1141-3. 1998
Cognitive function in nondemented older women who took estrogen after menopause.. 50:368-73. 1998
Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study.. 49:1513-21. 1997
An association between head circumference and Alzheimer's disease in a population-based study of aging and dementia.. 49:30-7. 1997
Participation in clinical trials and long-term outcomes in Alzheimer's disease.. 49:38-43. 1997
Dementia after stroke increases the risk of long-term stroke recurrence.. 48:1317-25. 1997
Mutation of the prion protein gene at codon 208 in familial Creutzfeldt-Jakob disease.. 47:1305-12. 1996
A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease.. 47:256-9. 1996
Neurologic consequences of HTLV-II infection in injection-drug users.. 46:1556-60. 1996
The Clinical Dementia Rating scale: community-based validation of "profound' and "terminal' stages.. 46:1746-9. 1996
Noninvasive perfusion MRI in Alzheimer's disease: a preliminary report.. 47:1339-42. 1996
Prion disease (PrP-A117V) presenting with ataxia instead of dementia.. 45:2042-50. 1995
Consistency of clinical diagnosis in a community-based longitudinal study of dementia and Alzheimer's disease.. 45:2159-64. 1995
Neuropsychological changes in a prospectively followed cohort of homosexual and bisexual men with and without HIV infection.. 45:467-72. 1995
Neuropsychological characteristics of preclinical dementia in Parkinson's disease.. 45:1691-6. 1995
Neuropsychological detection and characterization of preclinical Alzheimer's disease.. 45:957-62. 1995
Neuropsychological test performance in African-American and white patients with Alzheimer's disease.. 45:2207-11. 1995
Plasmapheresis in fulminant acute disseminated encephalomyelitis.. 45:824-7. 1995
Subtle extrapyramidal signs and incident dementia: a follow-up analysis.. 45:-. 1995
Kennedy's disease.. 43:2424-5. 1993
Word comprehension in temporal cortex and Wernicke area: A PPA perspective 2019
Rapid Revascularization of Simultaneous Bilateral ICA Occlusions causing Coma 2018
Word comprehension in temporal cortex and Wernicke area 2018
Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population 2016
Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. 2016
Rapid Revascularization of Simultaneous Bilateral ICA Occlusions causing Coma 2018

Clin-STAR Database

Neurology Journal

Overview

publication venue for

Identity

International Standard Serial Number (ISSN)